Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT06528873

COMS for Chronic Ulcers Treatment

Led by Sebastian Probst · Updated on 2026-05-08

122

Participants Needed

10

Research Sites

52 weeks

Total Duration

On this page

Sponsors

S

Sebastian Probst

Lead Sponsor

M

Medical University of Vienna

Collaborating Sponsor

AI-Summary

What this Trial Is About

Chronic leg and foot ulcers are defined as wounds that fail to heal in a timely manner, typically persisting for over 4 to 8 weeks without substantial healing despite standard care. These ulcers often result from macro- and microvascular disorders, the most common being chronic venous insufficiency (CVI), alone or with peripheral artery disease (PAD) or microangiopathy. Despite different causes, chronic vascular-origin wounds share similar biological traits and require the same physiological processes for healing. Vascular issues hinder blood perfusion, reducing oxygen, nutrients, and growth factors, leading to decreased energy metabolism and impaired cell functions necessary for proliferation, extracellular matrix production, angiogenesis, and tissue regeneration. Reduced blood supply also limits leukocyte function, compromising the immune response and leading to persistent inflammation and infection. Consequently, these wounds cannot effectively heal, showing prolonged inflammation, persistent infections, and cellular senescence. Best practice wound care includes compression therapy and physical activity for venous ulcers, and angioplasty, surgery, or bypass for arterial ulcers. These treatments aim to improve blood flow, reduce venous stasis, and enhance venous return. Compression therapy and physical activity lower hydrostatic pressure in the lower limb, while angioplasty and surgery remove arterial blockages or create new blood flow routes. Recent studies highlight the role of mechano-sensitive (MS) ion channels in skin cell processes and their dysfunction in dermatological disorders. Magnetic stimulation can activate MS TRCP1 channels, enhancing mitochondrial respiration and mitochondriogenesis via the Ca2+/CalModulin(CaM)/NFAT/PGC-1α pathway. Ca2+-activated calmodulin also catalyzes nitric oxide (NO), promoting vasodilation and tissue perfusion. Bimodal red and near-infrared photobiomodulation can further increase mitochondrial respiration and ATP production by activating Cytochrome C oxidase and mitigating NO-induced downregulation. This synergistic mechanism of concurrent optical and magnetic stimulation (COMS) may amplify Ca2+ and NO-mediated processes like cell proliferation, migration, vasodilation, and angiogenesis while resolving inflammation. Thus, COMS may offer a promising therapy for chronic, inflammation-prone wounds. The effectiveness of COMS has yet to be validated in large-scale studies. This proposal aims to assess the impact of COMS therapy combined with standard care versus standard care alone on healing, wound closure, recurrence, pain, quality of life, economic outcomes, and device usability in patients with venous leg ulcers (VLU) and VLU associated with PAD in a large-scale multicentric randomized controlled trial.

CONDITIONS

Official Title

COMS for Chronic Ulcers Treatment

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Clinical diagnosis of venous leg ulcer (VLU) or VLU with peripheral arterial disease (PAD)
  • Ankle-brachial index (ABI) between 0.5 and 1.3 or ankle pressure greater than 60 mmHg
  • Ulcer size between 2 and 50 cm² after debridement at screening
  • Ulcer duration longer than 30 days and less than 2 years
  • For patients with diabetes, HbA1c of 12% or less at screening
  • Able and willing to provide written informed consent prior to study procedures
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding
  • Malignancy in the ulcer area
  • Use of photosensitizing medication within 30 days
  • Severe immunosuppression, including chronic corticosteroid use over 10 mg/day prednisolone equivalent
  • NYHA class III or IV heart failure
  • End-stage renal disease requiring dialysis
  • Ulcer area reduction greater than 30% during run-in phase
  • Active infection requiring systemic antibiotics at baseline
  • Use of advanced wound therapies within 2 weeks prior to screening (e.g., negative pressure wound therapy, skin substitutes, hyperbaric oxygen)
  • Participation in another interventional clinical trial within 30 days

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

Medizinische Universität Graz

Graz, Austria

Not Yet Recruiting

2

Medizinische Universität Wien

Vienna, Austria

Not Yet Recruiting

3

Augustines's Clinic

Malestroit, France

Not Yet Recruiting

4

Universitätsklinikum Essen

Essen, Germany

Not Yet Recruiting

5

University Clinic Hamburg-Eppendorf

Hamburg, Germany

Not Yet Recruiting

6

Jura Hospital

Delémont, Switzerland

Not Yet Recruiting

7

Venenklinik Bellevue

Kreuzlingen, Switzerland

Actively Recruiting

8

Cité Générations

Onex, Switzerland

Not Yet Recruiting

9

Spital Thun

Thun, Switzerland

Not Yet Recruiting

10

University Hospital

Zurich, Switzerland

Not Yet Recruiting

Loading map...

Research Team

S

Sebastian Probst, Prof. Dr.

CONTACT

C

Camille Saini, Dr.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

DEVICE_FEASIBILITY

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here